Martin G. Sauer

Martin G. Sauer

Auto-generated profile, based on publicly available information

Martin G. Sauer

Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ABAgnes Bonifacius
Agnes Bonifacius
BLBritta Lamottke
Britta Lamottke
STSabine Tischer-Zimmermann
Sabine Tischer-Zimmermann
RSRebecca Schultze-Florey
Rebecca Schultze-Florey
LGLilia Goudeva
Lilia Goudeva
BMBritta Maecker-Kolhoff
Britta Maecker-Kolhoff
BACKGROUND. Adoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications. METHODS. We provide results of a personalized T cell manufacturing program evaluating donor, patient, T cell product, and outcome data. Patient-tailored clinical-grade EBV-specific cytotoxic T lymphocyte (EBV-CTL) products from stem cell donors (SCDs), related third-party donors (TPDs), or unrelated TPDs from the allogeneic T cell donor registry (alloCELL) at Hannover Medical School were manufactured by immunomagnetic selection using a CliniMACS Plus or Prodigy device and the EBV PepTivators EBNA-1 and Select. Consecutive manufacturing processes were evaluated, and patient outcome and side effects were retrieved by retrospective chart analysis. RESULTS. Forty clinical-grade EBV-CTL products from SCDs, related TPDs, or unrelated TPDs were generated for 37 patients with refractory EBV infections or EBV-associated malignancies with and without a history of transplantation, within 5 days (median) after donor identification. Thirty-four patients received 1–14 EBV-CTL products (fresh and cryopreserved). EBV-CTL transfer led to a complete response in 20 of 29 patients who were evaluated for clinical response. No infusion-related toxicity was reported. EBV-specific T cells in patients’ blood were detectable in 16 of 18 monitored patients (89%) after transfer, and their presence correlated with clinical response. CONCLUSION. Personalized clinical-grade manufacture of EBV-CTL products via immunomagnetic selection from SCDs, related TPDs, or unrelated TPDs in a timely manner is feasible. Overall, EBV-CTLs were clinically effective and well tolerated. Our data suggest EBV-CTL transfer as a promising therapeutic approach for immunocompromised patients with refractory EBV-associated diseases beyond HSCT, as well as patients with preexisting organ dysfunction. TRIAL REGISTRATION. Not applicable. FUNDING. This study was funded in part by the German Research Foundation (DFG, 158989968/SFB 900), the Deutsche Kinderkrebsstiftung (DKS 2013.09), Wilhelm-Sander-Stiftung (reference 2015.097.1), Ellen-Schmidt-Program of Hannover Medical School, and German Federal Ministry of Education and Research (reference 01EO0802).

8 January 2007 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
MSM Sauer
M Sauer
CZC Zeidler
C Zeidler
BMB Meissner
B Meissner
KRK Rehe
K Rehe
AHA Hanke
A Hanke
KSK-W Sykora
K-W Sykora

1 January 2015 in Journal of Biological Engineering
Verified
Journal Article
Open access
PDF file
SHSayed S Hoseini
Sayed S Hoseini
MSMartin G Sauer
Martin G Sauer
Over the last decades, molecular cloning has transformed biological sciences. Having profoundly impacted various areas such as basic science, clinical, pharmaceutical, and environmental fields, the use of recombinant DNA has successfully started to enter the field of cellular engineering. Here, the polymerase chain reaction (PCR) represents one of the most essential tools. Due to the emergence of novel and efficient PCR reagents, cloning kits, and software, there is a need for a concise and comprehensive protocol that explains all steps of PCR cloning starting from the primer design, performing PCR, sequencing PCR products, analysis of the sequencing data, and finally the assessment of gene expression. It is the aim of this methodology paper to provide a comprehensive protocol with a viable example for applying PCR in gene cloning.

14 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MMMichael Morgan
Michael Morgan
AKArnold Kloos
Arnold Kloos
DLDaniela Lenz
Daniela Lenz
NKNadine Kattre
Nadine Kattre
JNJuliette Nowak
Juliette Nowak
Axel SchambachAxel Schambach
Axel Schambach
Anti-cancer activity can be improved by engineering immune cells to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens. Retroviral vector gene transfer strategies allow stable and durable transgene expression. Here, we used alpharetroviral vectors to modify NK-92 cells, a natural killer cell line, with a third-generation CAR designed to target the IL-3 receptor subunit alpha (CD123), which is strongly expressed on the surface of acute myeloid leukemia (AML) cells. Alpharetroviral vectors also contained a transgene cassette to allow constitutive expression of human IL-15 for increased NK cell persistence in vivo. The anti-AML activity of CAR-NK-92 cells was tested via in vitro cytotoxicity assays with the CD123+ AML cell line KG-1a and in vivo in a patient-derived xenotransplantation CD123+ AML model. Unmodified NK-92 cells or NK-92 cells modified with a truncated version of the CAR that lacked the signaling domain served as controls. Alpharetroviral vector-modified NK-92 cells stably expressed the transgenes and secreted IL-15. Anti-CD123-CAR-NK-92 cells exhibited enhanced anti-AML activity in vitro and in vivo as compared to control NK-92 cells. Our data (1) shows the importance of IL-15 expression for in vivo persistence of NK-92 cells, (2) supports continued investigation of anti-CD123-CAR-NK cells to target AML, and (3) points towards potential strategies to further improve CAR-NK anti-AML activity.

2 October 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
MSMartin G. Sauer
Martin G. Sauer
PLPeter J. Lang
Peter J. Lang
MAMichael H. Albert
Michael H. Albert
PBPeter Bader
Peter Bader
UCUrsula Creutzig
Ursula Creutzig
ABArndt Borkhardt
Arndt Borkhardt

2 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MMMarcel Maluski
Marcel Maluski
AGArnab Ghosh
Arnab Ghosh
JHJessica Herbst
Jessica Herbst
VSVanessa Scholl
Vanessa Scholl
RBRolf Baumann
Rolf Baumann
MSMartin G. Sauer
Martin G. Sauer
The transcription factor B cell CLL/lymphoma 11B (BCL11B) is indispensable for T lineage development of lymphoid progenitors. Here, we show that chimeric antigen receptor (CAR) expression during early phases of ex vivo generation of lymphoid progenitors suppressed BCL11B, leading to suppression of T cell–associated gene expression and acquisition of NK cell–like properties. Upon adoptive transfer into hematopoietic stem cell transplant recipients, CAR-expressing lymphoid progenitors differentiated into CAR-induced killer (CARiK) cells that mediated potent antigen-directed antileukemic activity even across MHC barriers. CD28 and active immunoreceptor tyrosine–based activation motifs were critical for a functional CARiK phenotype. These results give important insights into differentiation of murine and human lymphoid progenitors driven by synthetic CAR transgene expression and encourage further evaluation of ex vivo–generated CARiK cells for targeted immunotherapy.